The Lu Lab focuses on basic science and translational research of kidney development, congenital anomalies of the kidney and urinary tract (CAKUT), podocyte biology and injury, pericyte biology and injury, and discovery of novel drug targets for patient with chronic kidney disease. Lu Lab research program is supported by grants from the National Institutes of Health (NIH) and Pfizer Centers for Therapeutic Innovation.

Five selected publications:

1. Lu W et al. Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. American Journal Human Genetics, 2007. PMID 17357069
2. Fan X et al. Inhibitory effects of Robo2 on nephrin: a crosstalk between positive and negative signals regulating podocyte structure. Cell Reports, 2012. PMID: 22840396
3. Hwang DY, Kohl S, Fan X, et al. Mutations of the SLIT2-ROBO2 pathway genes SLIT2 and SRGAP1 confer risk for congenital anomalies of the kidney and urinary Tract. Human Genetics, 2015. PMID: 26026792
4. Rasouly HM et al. Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic kidney disease. Kidney International, 2016. PMID: 27591083
5. Fan X et al. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. Journal of Clinical Investigation, 2016. PMID: 27882344